<DOC>
	<DOCNO>NCT00050713</DOCNO>
	<brief_summary>This study evaluate safety effectiveness new immunosuppressive drug , sirolimus , reduce amount protein urine patient membranous nephropathy . This condition involve damage wall tiny blood vessel filter kidney call glomerulus , allow blood protein leak urine . Patients low blood protein level high blood cholesterol . Some patient may leg swell , impaired kidney function , blood vessel heart disease , risk embolus ( blood clot travel lung ) . Drugs currently use treat membranous nephropathy vary effectiveness among patient cause severe side effect . The Food Drug Administration approve sirolimus suppress immune system patient kidney transplant reduce risk organ rejection . The drug certain side effect cause problem patient treat immunosuppressant , : prednisone ( weight gain , round face , diabetes , weak fracture bone , cataract ) ; cyclophosphamide ( fertility problem , bladder injury bladder cancer , cancer ) ; chlorambucil ( fertility problem , seizure , acute leukemia , cancer ) ; cyclosporine ( kidney toxicity , increase facial hair , seizure ) . Patients 13 year age old idiopathic membranous nephropathy lupus membranous nephropathy may eligible study . Candidates must complete least one month treatment stable dose angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) . They screen medical history , physical examination , blood test , skin test exposure tuberculosis , examination infection , cancer , condition cause membranous nephropathy . Participants take sirolimus day 1 year , except first day treatment , take three dos quickly bring blood level drug therapeutic level . They undergo evaluation NIH Bethesda , Maryland , baseline ( start treatment ) 1- 4-month interval study . In addition , blood test every week first month every 2 week second month ; blood urine test month next 10 month treatment every 4 month 12-month period treatment stop . These test evaluate drug side effect response therapy , determine therapeutic benefit persist long-term treatment stop . Patients also ask optional kidney function test baseline evaluation end follow-up period measure kidney filtration blood flow rate . Those participate give fluid substance vein accurately measure kidney function . They blood urine sample collect four time 1-hour period drinking fluid increase urine output . Patients experience substantial increase proteinuria substantial decrease kidney function course treatment stop take sirolimus take study .</brief_summary>
	<brief_title>Sirolimus Therapy Idiopathic Lupus Membranous Nephropathy</brief_title>
	<detailed_description>This phase 2 trial evaluate safety effectiveness new immunosuppressive drug , sirolimus , patient idiopathic lupus membranous nephropathy . Patients ( age great equal 13 year ) invite participate persistent nephrotic range proteinuria despite standard treatment angiotensin convert enzyme inhibitor angiotensin receptor blocker least one month , unless intolerant . These individual risk renal function deterioration well cardiovascular thrombo-embolic complication nephrotic syndrome . Renal function , degree proteinuria side effect monitor closely throughout study . Physiologic measure glomerular function examine study entry conclusion trial .</detailed_description>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>INCLUSION CRITERIA : Ability willingness provide inform consent ( adult great equal 18 year ) assent ( child great equal 13 year ) aspect study full information provide . Nephrotic range proteinuria persist least 3 month . Nephrotic range proteinuria persist despite angiotensin antagonist therapy ( ACE inhibitor ARB ) least month , unless intolerant . If patient start ACE inhibitor therapy refer NIH , plan start lisinopril 5 mg daily . We advance dose ACE inhibitor tolerate . Nephrotic range proteinuria , define 24 hour urine protein excretion great equal 3.5 g/d , must document least two 24 hour urine collection obtain month prior initiate sirolimus . Incomplete urine collection ( base inadequate creatinine excretion ) exclude . Renal biopsy must reveal typical change membranous nephropathy light electron microscopy . SLE define presence least 4 criterion establish American Rheumatism Association ( Lupus Membranous Nephropathy ) evidence secondary form membranous nephropathy ( Idiopathic Membranous Nephropathy ) . EXCLUSION CRITERIA : Intolerance sirolimus prior use sirolimus membranous nephropathy . Estimated GFR le 30 mL/min/1.73 ( 2 ) ( determine 5 variable version MDRD Study prediction equation ) . Immunosuppressive medication experimental medication type twomonth period prior initiate sirolimus , follow two exception : First , patient lupus membranous nephropathy permit receive modest dos corticosteroid ( equivalent prednisone 10mg/day ) control extrarenal manifestation SLE twomonth period prior start sirolimus treatment . Second , patient worsen nephrotic syndrome ( urine protein excretion rate double +/or serum albumin decrease great equal 1.0 g/ dL le 2.5 g/dL least 2 determination follow previous immunosuppressive treatment ) fulfill follow criterion : ) prednisone least 2 week perform baseline evaluation start sirolimus ( patient idiopathic membranous nephropathy ) : b ) lowdose corticosteroid ( equivalent prednisone 10 mg/day ) least 2 week perform baseline evaluation start sirolimus ( patient lupus membranous nephropathy ) ; c ) cyclosporine least 2 week perform baseline evaluation start sirolimus ; ) cyclophosphamide , chlorambucil , azathioprine mycophenolate mofetil least 4 week perform baseline evaluation start sirolimus ; Children le 13.0 year . Active acute chronic infection require antimicrobial therapy serious viral infection ( e.g . HIV , hepatitis , herpes zoster ) . Patients reactive PPD must complete 6 12 month course isoniazid recommend infectious disease consultant . Patients nonreactive PPD nonreactive anergy panel must complete 6 12 month course isoniazid recommend infectious disease consultant . Pregnant woman , nurse mother individual ( men woman ) practice birth control . Uncontrolled hypertension , define BP great 140/90 great 25 % measurement . Blood pressure measure 3 time clinic visit patient sit quietly least 5 minute . Thus least 6 BP determination record prior initiate sirolimus therapy . Chronic liver disease sufficiently severe impair sirolimus metabolism ; would include prolonged prothrombin time . Patients abnormal liver function test evaluate Hepatology Consult Service determine whether protocol participation appropriate . Basal thrombocytopenia less 100,000 cells/microliters absolute neutrophil count less 2000 cells/microliters hematocrit less 30 . Cancer diagnosis cancer recurrence within precede 5 year , exclude basal cell carcinoma skin . Routine use NSAIDS , define NSAID use two dos week . Clinically significant medical condition , opinion investigator , could increase subject risk participate study could confound interpretation result study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 7, 2015</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Nephrotic Syndrome</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>